Asset Details
Do you wish to reserve the book?
Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways
Do you wish to request the book?
Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ganoderic acid hinders renal fibrosis via suppressing the TGF-β/Smad and MAPK signaling pathways
2020
Overview
Renal fibrosis is considered as the pathway of almost all kinds of chronic kidney diseases (CKD) to the end stage of renal diseases (ESRD). Ganoderic acid (GA) is a group of lanostane triterpenes isolated from
Ganoderma lucidum
, which has shown a variety of pharmacological activities. In this study we investigated whether GA exerted antirenal fibrosis effect in a unilateral ureteral obstruction (UUO) mouse model. After UUO surgery, the mice were treated with GA (3.125, 12.5, and 50 mg· kg
−1
·d
−
1
, ip) for 7 or 14 days. Then the mice were sacrificed for collecting blood and kidneys. We showed that GA treatment dose-dependently attenuated UUO-induced tubular injury and renal fibrosis; GA (50 mg· kg
−1
·d
−
1
) significantly ameliorated renal disfunction during fibrosis progression. We further revealed that GA treatment inhibited the extracellular matrix (ECM) deposition in the kidney by suppressing the expression of fibronectin, mainly through hindering the over activation of TGF-β/Smad signaling. On the other hand, GA treatment significantly decreased the expression of mesenchymal cell markers alpha-smooth muscle actin (α-SMA) and vimentin, and upregulated E-cadherin expression in the kidney, suggesting the suppression of tubular epithelial-mesenchymal transition (EMT) partially via inhibiting both TGF-β/Smad and MAPK (ERK, JNK, p38) signaling pathways. The inhibitory effects of GA on TGF-β/Smad and MAPK signaling pathways were confirmed in TGF-β1-stimulated HK-2 cell model. GA-A, a GA monomer, was identified as a potent inhibitor on renal fibrosis in vitro. These data demonstrate that GA or GA-A might be developed as a potential therapeutic agent in the treatment of renal fibrosis.
Publisher
Springer Singapore,Nature Publishing Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Dose-Response Relationship, Drug
/ Fibrosis
/ Humans
/ Kidneys
/ Male
/ MAP Kinase Signaling System - drug effects
/ Mice
/ Signal Transduction - drug effects
/ Smad Proteins - antagonists & inhibitors
/ Surgery
/ Transforming Growth Factor beta - antagonists & inhibitors
/ Transforming Growth Factor beta - metabolism
/ Transforming growth factor-b1
/ Triterpenes - administration & dosage
/ Ureteral Obstruction - drug therapy
/ Ureteral Obstruction - metabolism
/ Ureteral Obstruction - surgery
/ Vaccine
/ Vimentin
